Precede Biosciences has secured $63.5 million in funding, an investment aimed at accelerating its mission to transform disease diagnosis and medicine development. The company is dedicated to addressing significant gaps in the medical and research community's collective ability to access and understand disease-defining biology precisely when it matters most for patient care and therapeutic intervention.
This substantial capital infusion will be instrumental in accelerating the development and commercialization of Precede Bio's innovative platform. The company has pioneered a simple blood test designed to uncover actionable disease-defining transcriptional biology. This funding round signifies strong investor confidence in Precede Bio's unique approach to providing high-resolution, dynamic insights into disease activity from a minimally invasive sample.
Precede Bio's unique genome-wide platform profiles circulating chromatin and the DNA methylome. This advanced technology delivers unprecedented resolution into the dynamic activity of individual genes and pathways within diseased tissues, all from just 1mL of plasma. This method aims to provide crucial biological information that can guide more effective treatment decisions and streamline drug development processes.
By partnering with developers of new medicines and advancing its own diagnostic tests, Precede Biosciences aims to significantly improve the success rate of new medicine development efforts. The company envisions a future where anyone can receive a precise, minimally invasive diagnosis and treatment that is tailored to the specific biology of their disease. This funding round strategically positions Precede Biosciences for substantial growth and expansion as it works towards making its advanced diagnostic capabilities widely accessible and impactful in clinical practice.
